Silver Spring, MD, United States of America

Andrew Lees

USPTO Granted Patents = 30 


 

Average Co-Inventor Count = 1.6

ph-index = 11

Forward Citations = 445(Granted Patents)


Location History:

  • Baltimore, MD (US) (1996 - 1999)
  • Silver Spring, MD (US) (1997 - 2021)

Company Filing History:


Years Active: 1996-2024

Loading Chart...
Loading Chart...
Loading Chart...
30 patents (USPTO):Explore Patents

Title: Andrew Lees: Innovator in Recombinant Protein Production

Introduction

Andrew Lees, a prolific inventor based in Silver Spring, MD, has made significant contributions to the field of biotechnology. With an impressive portfolio of 30 patents, Lees exemplifies innovation in the production of recombinant proteins. His work focuses on improving methodologies for producing high levels of soluble recombinant proteins, which are essential for various medical and industrial applications.

Latest Patents

Among his most recent patents, Lees has developed innovative processes for the production of soluble recombinant proteins devoid of N-terminal methionine. His inventions include methods for enzymatically removing the f-met group at the 5'-terminus of recombinant proteins. These processes utilize cells that possess mutations in disulfide reductase genes, resulting in reduced disulfide reductase activity, thereby enhancing the yield of soluble CRM protein. Furthermore, his patents also cover purification methods for CRM as well as the characterization of correctly folded CRM proteins, showcasing his commitment to advancing production techniques in biotechnology.

Career Highlights

Throughout his career, Andrew Lees has been associated with notable organizations that have refined his expertise in the life sciences. He has worked at the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and Fina Biosolutions, LLC, where he has been instrumental in developing cutting-edge solutions in health care and protein production.

Collaborations

Lees has collaborated with distinguished professionals in his field, including James J. Mond and Richard F. Schuman. These partnerships have undoubtedly enriched his work, promoting a multidisciplinary approach to solving complex challenges in biotechnological research and development.

Conclusion

Andrew Lees continues to be a leading figure in the realm of recombinant protein production. Through his innovations and collaborative efforts, he is paving the way for advancements that could have a far-reaching impact in the medical and scientific community. His extensive patent portfolio is a testament to his dedication to research and development in biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…